Genmab, AbbVie announce new data from Phase 1/2 EPCORE NHL-1 trial

Genmab (GMAB) and AbbVie (ABBV) announced new data from the ongoing phase 1/2 EPCORE NHL-1 clinical trial investigating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate of 82 percent, a complete response rate of 63 percent and minimal residual disease negativity rate of 67 percent in patients with relapsed/refractory follicular lymphoma. The presentation included data from an optimized step-up dosing schedule for FL patients showing a reduction in risk and severity of Grade 2+ cytokine release syndrome, a common side effect of T-cell engaging cancer treatments. These results were presented today at the 2023 65th Annual Meeting and Exposition of the American Society of Hematology. Safety findings were consistent with previous epcoritamab trials, and epcoritamab was generally well tolerated. TEAEs leading to treatment discontinuation occurred in 19 percent of patients, and Grade 5 TEAEs occurred in 13 patients.